Committed to a $10 billion U.S. expansion over the next decade to grow its manufacturing footprint, including funding four new U.S. production facilities dedicated to active pharmaceutical ingredients, finished drug products, peptide therapeutics, and medical devices.

Announced a $900 million expansion of its biologics manufacturing facility in New Albany, Ohio, bringing Amgen’s total investment in Ohio to $1.4 billion and increasing the site’s workforce to about 750 employees. 

Broke ground on a new biologics manufacturing plant to produce Keytruda (pembrolizumab) and other biologic medicine. Expected to create 500 full-time roles and 4,000 construction jobs.

Part of a $70 billion U.S. investment plan.